局部晚期食管癌新辅助治疗的研究进展  

Recent progress in neoadjuvant therapy for locally advanced esophageal cancer

作　　者：陈志富 徐利本[1] 王燕[1] 吴朝阳[1] CHEN Zhi-Fu;XU Li-Ben;WANG Yan;WU Chao-Yang(Radiotherapy Department,the Affiliated People's Hospital of Jiangsu University,Zhenjiang 212000,China)

机构地区：[1]江苏大学附属人民医院肿瘤放疗科,镇江212000

出　　处：《生命科学》2024年第2期275-282,共8页Chinese Bulletin of Life Sciences

基　　金：江苏大学临床医学科技发展基金项目(JLY2018-0001)。

摘　　要：食管癌是世界范围内恶性程度高、预后不良的肿瘤之一。手术治疗是局部晚期食管癌治疗的首选方式,但单纯手术治疗效果不佳,总体5年生存率较低。因此,局部晚期食管癌的治疗更倾向于手术联合多种模式的治疗。在局部晚期食管癌中,新辅助治疗展示出了明显的生存获益、良好的临床疗效以及可接受的毒性反应,成为局部晚期食管癌的标准治疗模式之一。新辅助治疗主要包括新辅助化疗、新辅助放化疗、新辅助免疫治疗。本文就局部晚期食管癌新辅助治疗的研究进展进行综述。Esophageal cancer is one of the tumors with high malignancy and poor prognosis in the worldwide.Surgical treatment is the first-choice for the locally advanced esophageal cancer,but simple surgical treatment is not effective and the overall 5-year survival rate remains low.Therefore,the treatment of locally advanced esophageal cancer is more inclined to be surgery combined with multiple modes of treatment.In locally advanced esophageal cancer,neoadjuvant therapy has demonstrated significant survival benefits,good clinical efficacy,and acceptable toxic reactions,becoming one of the standard treatment modes.Neoadjuvant therapy mainly includes neoadjuvant chemotherapy,neoadjuvant radiotherapy and chemotherapy and neoadjuvant immunotherapy.This article reviews the research progress of neoadjuvant therapy in locally advanced esophageal cancer.

关 键 词：局部晚期食管癌 新辅助化疗 新辅助放化疗 新辅助免疫治疗 

分 类 号：R735.1[医药卫生—肿瘤]